Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Jakafi (ruxolitinib) – Treatment of Myelofibrosis

Drug (Brand / Generic)

Jakafi / INCB18424/ ruxolitinib

Company / Licensee

Incyte Corp / Novartis

Therapy Class

Janus kinase (JAK) inhibitor

Current Indication

Myelofibrosis and Polycythemia Vera (PV)

Market Sector

Oncology

Development Status

Approved in US and Europe
Expand
Close
Close
Close

Go Top